These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7888109)

  • 41. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland.
    Nelson CP; Gupta P; Napier CM; Nahorski SR; Challiss RA
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1255-65. PubMed ID: 15140916
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of PCS1055, a novel muscarinic M4 receptor antagonist.
    Croy CH; Chan WY; Castetter AM; Watt ML; Quets AT; Felder CC
    Eur J Pharmacol; 2016 Jul; 782():70-6. PubMed ID: 27085897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.
    Moser PC; Bergis OE; Jegham S; Lochead A; Duconseille E; Terranova JP; Caille D; Berque-Bestel I; Lezoualc'h F; Fischmeister R; Dumuis A; Bockaert J; George P; Soubrié P; Scatton B
    J Pharmacol Exp Ther; 2002 Aug; 302(2):731-41. PubMed ID: 12130738
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diphenidol-related diamines as novel muscarinic M4 receptor antagonists.
    Varoli L; Andreani A; Burnelli S; Granaiola M; Leoni A; Locatelli A; Morigi R; Rambaldi M; Bedini A; Fazio N; Spampinato S
    Bioorg Med Chem Lett; 2008 May; 18(9):2972-6. PubMed ID: 18395442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy.
    Utsuki T; Uchimura N; Irikura M; Moriuchi H; Holloway HW; Yu QS; Spangler EL; Mamczarz J; Ingram DK; Irie T; Greig NH
    J Pharmacol Exp Ther; 2007 Apr; 321(1):353-61. PubMed ID: 17255466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
    Zueva IV; Semenov VE; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS
    Int J Risk Saf Med; 2015; 27 Suppl 1():S69-71. PubMed ID: 26639718
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acetylcholinesterase inhibitors activate septohippocampal GABAergic neurons via muscarinic but not nicotinic receptors.
    Wu M; Newton SS; Atkins JB; Xu C; Duman RS; Alreja M
    J Pharmacol Exp Ther; 2003 Nov; 307(2):535-43. PubMed ID: 12966162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The dual-acting AChE inhibitor and H3 receptor antagonist UW-MD-72 reverses amnesia induced by scopolamine or dizocilpine in passive avoidance paradigm in rats.
    Sadek B; Khan N; Darras FH; Pockes S; Decker M
    Physiol Behav; 2016 Oct; 165():383-91. PubMed ID: 27568232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases.
    Salmon M; Luttmann MA; Foley JJ; Buckley PT; Schmidt DB; Burman M; Webb EF; DeHaas CJ; Kotzer CJ; Barrett VJ; Slack RJ; Sarau HM; Palovich MR; Lainé DI; Hay DW; Rumsey WL
    J Pharmacol Exp Ther; 2013 May; 345(2):260-70. PubMed ID: 23435542
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
    Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
    J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
    Olianas MC; Maullu C; Onali P
    Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic administration of the potential countermeasure huperzine reversibly inhibits central and peripheral acetylcholinesterase activity without adverse cognitive-behavioral effects.
    Myers TM; Sun W; Saxena A; Doctor BP; Bonvillain AJ; Clark MG
    Pharmacol Biochem Behav; 2010 Jan; 94(3):477-81. PubMed ID: 19909771
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Anticholinesterases; peripheral and central effects].
    Sato T; Nakatsuka H
    Masui; 2013 Jan; 62(1):19-26. PubMed ID: 23431890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Muscarinic acetylcholine receptors in the brain of the zebrafish (Danio rerio) measured by radioligand binding techniques.
    Williams FE; Messer WS
    Comp Biochem Physiol C Toxicol Pharmacol; 2004 Apr; 137(4):349-53. PubMed ID: 15228953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antagonism of muscarinic receptors in the rabbit iris-ciliary body by 8-OH-DPAT and other 5-HT1A receptor agonists.
    Chidlow G; Osborne NN
    J Neural Transm (Vienna); 1997; 104(10):1015-25. PubMed ID: 9503254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
    Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
    Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acetylcholinesterase immobilization and characterization, and comparison of the activity of the porous silicon-immobilized enzyme with its free counterpart.
    Saleem M; Rafiq M; Seo SY; Lee KH
    Biosci Rep; 2016 Feb; 36(2):. PubMed ID: 26839417
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.
    Darvesh AS; Carroll RT; Geldenhuys WJ; Gudelsky GA; Klein J; Meshul CK; Van der Schyf CJ
    Expert Opin Drug Discov; 2011 Feb; 6(2):109-127. PubMed ID: 21532928
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist.
    Emmerling MR; Gregor VE; Schwarz RD; Scholten JD; Callahan MJ; Lee C; Moore CJ; Raby C; Lipinski WJ; Davis RE
    Mol Neurobiol; 1994; 9(1-3):93-106. PubMed ID: 7888109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization.
    Schwarz RD; Callahan MJ; Coughenour LL; Dickerson MR; Kinsora JJ; Lipinski WJ; Raby CA; Spencer CJ; Tecle H
    J Pharmacol Exp Ther; 1999 Nov; 291(2):812-22. PubMed ID: 10525104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.